COMMUNIQUÉS West-GlobeNewswire

Sol-Gel Announces Positive Top-Line Results from Epsolay® Phase 3 Program in Papulopustular Rosacea
08/07/2019
All primary and secondary endpoints achieved in both Phase 3 clinical trials Rapid efficacy demonstrated, with statistical significance reached as early as Week 2 compared with vehicle Favorable safety and tolerability [...]
Share buy-back week 27/2019
08/07/2019
Announcement 8 July 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling up [...]
Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
08/07/2019
Study 404 met its primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (p<0.001; effect size = 0.56). Study 404 also met its key [...]
Batavia Biosciences receives $2.2 million follow-up grant from PATH to support new tools for polio eradication era
08/07/2019
Leiden, 4 Jul 2019 – Today, Batavia Biosciences announces it received a follow-up grant of $2.2 million from PATH – a global organization dedicated to health equity – to develop and manufacture novel oral poliovirus [...]
Inspire Medical Systems, Inc. Announces UnitedHealthcare Coverage for Inspire Therapy for the Treatment of Obstructive Sleep Apnea
08/07/2019
MINNEAPOLIS, July 08, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (the “Company” or “Inspire”), a medical technology company focused on the development and commercialization of innovative and [...]
Newly Published Nicotinamide Riboside Study Further Demonstrates Safety of Sustained Niagen Supplementation and Optimal Dosing Levels
08/07/2019
New clinical study shows Niagen® supplementation safe and effective at the recommended daily serving; statistically significant sustained blood NAD+ levels LOS ANGELES, July 08, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp [...]
Transactions under Novozymes’ stock buyback program
08/07/2019
Please read the full announcement in the attached PDF Attachment 2019_22_Stock_Buybackprogram_EN
NoorLine lance un site Web à visée thérapeutique adapté à chaque culture et disponible 24 h/24 gratuitement
08/07/2019
DÉTROIT (États-Unis), 08 juill. 2019 (GLOBE NEWSWIRE) -- NoorLine, une ligne d'écoute anonyme et gratuite, a été lancée à Détroit cette semaine pour proposer un soutien moral anonyme par des pairs 24 h/24 aux personnes [...]
Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors
08/07/2019
Subcutaneous MarzAA (FVIIa) prophylaxis reduced the annualized bleeding rate by more than 90% compared with pretreatment Data presented at the 2019 Congress of the International Society on Thrombosis and Haemostasis [...]
AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
08/07/2019
Paris, 8 th July 2019, 7.30am Publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration AB Science SA (NYSE Euronext - [...]
AB Science annonce la publication de l’étude positive de phase 2/3 du masitinib dans la SLA dans la revue Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
08/07/2019
Paris, 8 juillet 2019, 7h30 Publication de l’étude positive de phase 2/3 du masitinib dans la SLA dans la revue Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration AB Science SA (NYSE Euronext - FR0010557264 [...]
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
08/07/2019
Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
Acacia Pharma Plans to Resubmit the BARHEMSYS® NDA in Q3 2019
08/07/2019
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 8 July 2019: Acacia Pharma Group plc (“Acacia Pharma” or [...]
Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
08/07/2019
BEIJING, China and CAMBRIDGE, Mass., July 07, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Tetra Bio-Pharma Comments on Recent Trading Activity at the Request of IIROC
05/07/2019
ORLEANS, Ontario, July 05, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (" Tetra " or the " Corporation ") a bio-pharmaceutical multifaceted corporation with its primary focus in cannabinoid‑based drug discovery and [...]
Shineco, Inc. Receives Notice of Nasdaq Non-Compliance Due to Delayed Annual Meeting
05/07/2019
BEIJING, July 05, 2019 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; Nasdaq: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, specialized textiles, and [...]
Acer Therapeutics Announces Restructuring and Update on Pipeline Programs
05/07/2019
Restructuring expected to extend cash runway through end of 2020 Acer plans to discuss EDSIVO™ CRL with FDA and will continue to advance additional pipeline products NEWTON, Mass., July 05, 2019 (GLOBE NEWSWIRE) -- Acer [...]
Novelion Therapeutics Receives Delisting Notifications
05/07/2019
VANCOUVER, British Columbia, July 05, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare [...]
TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer
05/07/2019
In this poor prognosis population, SM-88 demonstrated median overall survival (OS) of 6.4 months as of April 25, 2019 Efficacy indicators showed strong correlation with greater overall survival (OS). These indicators [...]

Pages